ES2096328T3 - Nuevo procedimiento para la esterificacion de la bacatina iii y de la desacetil-10 bacatina iii. - Google Patents

Nuevo procedimiento para la esterificacion de la bacatina iii y de la desacetil-10 bacatina iii.

Info

Publication number
ES2096328T3
ES2096328T3 ES93921980T ES93921980T ES2096328T3 ES 2096328 T3 ES2096328 T3 ES 2096328T3 ES 93921980 T ES93921980 T ES 93921980T ES 93921980 T ES93921980 T ES 93921980T ES 2096328 T3 ES2096328 T3 ES 2096328T3
Authority
ES
Spain
Prior art keywords
iii
bacatine
radical
formula
desacetil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93921980T
Other languages
English (en)
Inventor
Jean-Noel Denis
Andrew Greene
Jean-Manuel Mas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Application granted granted Critical
Publication of ES2096328T3 publication Critical patent/ES2096328T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epoxy Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PROCESO DE PREPARACION DE ESTERES DE LA BACATINA II O DE LA DESACETIL-10 BACATINA III DE FORMULA (I) POR ESTERIFICACION DE LA BACATINA III O DE LA DESACETIL-10 BACATINA III PROTEGIDA DE FORMULA (II) MEDIANTE UN ACIDO ACTIVADO DE FORMULA (III). LOS ESTERES DE FORMULA (I) SON UTILES PARA PREPARAR LOS DERIVADOS DEL TAXANO QUE TIENEN PROPIEDADES ANTILEUCEMICAS Y ANTITUMORALES NOTABLES. EN LAS FORMULAS (I), (II) Y (III), AR REPRESENTA UN RADICAL ARILO R1 REPRESENTA UN ATOMO DE HIDROGENO O UN RADICAL AROILO O UN RADICAL R4-O-CO-(R4 = ALCENILO, ALCINILO, ALCOILO, EVENTUALMENTE SUSTITUIDO, CICLOALCOILO, CICLOALCENILO, BICICLOALCOILO, FENILO, HETEROCICLILO) Y R2 REPRESENTA UN ATOMO DE HIDROGENO Y R 3 REPRESENTA UN GRUPO PROTECTOR DE LA FUNCION HIDROXI, O BIEN R1 SE DEFINE COMO ANTERIORMENTE Y R2 Y R3 JUNTO FORMAN UN HETEROCICLO SATURADO DE 5 O 6 ESLABONES, G1 REPRESENTA UN RADICAL ACETIL O UN GRUPO PROTECTOR DE LA FUNCION HIDROXI, G2 REPRESENTA UN GRUPO PROTECTOR DE LA FUNCION HIDROXI Y X REPRESENTAUN RADICAL ACILO, AROILO O UN ATOMO DE HALOGENO.
ES93921980T 1992-10-05 1993-10-04 Nuevo procedimiento para la esterificacion de la bacatina iii y de la desacetil-10 bacatina iii. Expired - Lifetime ES2096328T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9211739A FR2696464B1 (fr) 1992-10-05 1992-10-05 Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.

Publications (1)

Publication Number Publication Date
ES2096328T3 true ES2096328T3 (es) 1997-03-01

Family

ID=9434116

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93921980T Expired - Lifetime ES2096328T3 (es) 1992-10-05 1993-10-04 Nuevo procedimiento para la esterificacion de la bacatina iii y de la desacetil-10 bacatina iii.

Country Status (24)

Country Link
US (2) US5717103A (es)
EP (1) EP0663905B1 (es)
JP (1) JP3064419B2 (es)
KR (1) KR100290663B1 (es)
AT (1) ATE147734T1 (es)
AU (1) AU689446B2 (es)
CA (1) CA2146372C (es)
CZ (1) CZ284818B6 (es)
DE (1) DE69307526T2 (es)
DK (1) DK0663905T3 (es)
ES (1) ES2096328T3 (es)
FI (1) FI115909B (es)
FR (1) FR2696464B1 (es)
GR (1) GR3022286T3 (es)
HU (1) HU225973B1 (es)
MX (1) MX9305764A (es)
NO (1) NO313141B1 (es)
NZ (1) NZ256443A (es)
PL (1) PL178090B1 (es)
RU (1) RU2123493C1 (es)
SK (1) SK281035B6 (es)
TW (1) TW372234B (es)
WO (1) WO1994007876A1 (es)
ZA (1) ZA937316B (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2698361B1 (fr) * 1992-11-20 1995-01-13 Rhone Poulenc Rorer Sa Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
IL107950A (en) 1992-12-15 2001-04-30 Upjohn Co 7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ES2205663T3 (es) * 1993-06-11 2004-05-01 PHARMACIA & UPJOHN COMPANY Uso antineoplasico de delta 6,7-taxoles y composiciones farmaceuticas que los contienen.
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
KR100354309B1 (ko) * 1993-11-12 2003-01-06 파마시아 앤드 업존 캄파니 피리미딘-티오알킬및알킬에테르화합물
IL127598A (en) * 1994-01-28 2003-04-10 Upjohn Co Process for preparing isotaxol analogs
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
ATE223889T1 (de) * 1996-05-08 2002-09-15 Upjohn Co Oxazolidinester
US6150537A (en) * 1997-12-12 2000-11-21 Emory University Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents
JP4502338B2 (ja) * 1999-09-17 2010-07-14 株式会社横浜国際バイオ研究所 タキソイド化合物の製造法
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
CZ2003837A3 (cs) 2000-09-22 2004-12-15 Bristol-Myers Squibb Company Způsob pro snížení toxicity při kombinovaných chemoterapiích
CA2440935A1 (en) 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DE60220519T2 (de) * 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ITMI20021921A1 (it) * 2002-09-10 2004-03-11 Indena Spa Funzionalizzazione della posizione 14 dei nuclei tassanici e sintesi di nuovi derivati antitumorali.
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7407973B2 (en) 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
BRPI0709075A2 (pt) 2006-03-20 2011-10-11 Medigene Ag tratamento de cáncer de mama triplo receptor negativo
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
EP2296645B1 (en) 2008-05-22 2014-11-19 Galera Therapeutics, LLC Combination antitumor therapy
HUE028327T2 (en) 2008-06-06 2017-02-28 Neurmedix Inc A process for the preparation of 17-alkynyl-7-hydroxy steroids and related compounds
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
DK2956175T3 (da) 2013-02-15 2017-11-27 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
CN115504924A (zh) 2013-11-27 2022-12-23 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
HUE051255T2 (hu) 2014-02-19 2021-03-01 Aviv Therapeutics Inc Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére
JP6083815B2 (ja) * 2014-03-07 2017-02-22 立川ブラインド工業株式会社 タッセル
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
US10654875B2 (en) 2015-11-12 2020-05-19 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
CN109640961B (zh) 2016-06-01 2021-11-02 施维雅知识产权英国有限公司 聚亚烷基氧化物-天冬酰胺酶制剂及其制备和使用方法
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
JP7280827B2 (ja) 2017-01-18 2023-05-24 エクスマ バイオテック コーポレイション Ａｘｌまたはｒｏｒ２に対するキメラ抗原受容体およびその使用方法
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
CA3090129A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
TW202038994A (zh) 2019-01-14 2020-11-01 美商醫格耐免疫治療公司 重組痘瘡病毒及其使用方法
WO2020165730A1 (en) 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP7716623B2 (ja) 2019-04-02 2025-08-01 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 排出ポンプ－癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
WO2021116943A1 (en) 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
WO2021155028A1 (en) 2020-01-29 2021-08-05 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
CN116529267A (zh) 2020-06-04 2023-08-01 肯乔克蒂生物技术股份有限公司 Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法
AU2021310520A1 (en) 2020-07-14 2023-02-16 Pfizer Inc. Recombinant vaccinia virus
CA3193588A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
WO2022103603A1 (en) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
US12187810B2 (en) 2020-11-20 2025-01-07 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
US20250051471A1 (en) 2021-12-13 2025-02-13 William Robert Arathoon Living Trust Dated August 29, 2016 Anti-Abcb1 Antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34277A (en) * 1862-01-28 Improvement in lamps
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
USRE34277E (en) * 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2696460B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.

Also Published As

Publication number Publication date
NO951200L (no) 1995-03-29
HU9500970D0 (en) 1995-06-28
JP3064419B2 (ja) 2000-07-12
US5977375A (en) 1999-11-02
NZ256443A (en) 1996-07-26
WO1994007876A1 (fr) 1994-04-14
NO313141B1 (no) 2002-08-19
ATE147734T1 (de) 1997-02-15
FI951593L (fi) 1995-04-04
SK281035B6 (sk) 2000-11-07
RU2123493C1 (ru) 1998-12-20
MX9305764A (es) 1995-01-31
JPH08501787A (ja) 1996-02-27
FI115909B (fi) 2005-08-15
PL178090B1 (pl) 2000-02-29
GR3022286T3 (en) 1997-04-30
FR2696464A1 (fr) 1994-04-08
US5717103A (en) 1998-02-10
CA2146372C (fr) 2003-09-09
AU689446B2 (en) 1998-04-02
TW372234B (en) 1999-10-21
ZA937316B (en) 1994-04-22
FR2696464B1 (fr) 1994-11-10
CZ284818B6 (cs) 1999-03-17
DK0663905T3 (da) 1997-02-03
CA2146372A1 (fr) 1994-04-14
SK43895A3 (en) 1995-08-09
FI951593A0 (fi) 1995-04-04
AU5114893A (en) 1994-04-26
KR100290663B1 (ko) 2001-09-17
EP0663905B1 (fr) 1997-01-15
KR950703545A (ko) 1995-09-20
HUT72616A (en) 1996-05-28
CZ83995A3 (en) 1995-09-13
HU225973B1 (en) 2008-02-28
DE69307526D1 (de) 1997-02-27
DE69307526T2 (de) 1997-05-22
RU95110766A (ru) 1996-12-27
NO951200D0 (no) 1995-03-29
EP0663905A1 (fr) 1995-07-26
PL308239A1 (en) 1995-07-24

Similar Documents

Publication Publication Date Title
ES2096328T3 (es) Nuevo procedimiento para la esterificacion de la bacatina iii y de la desacetil-10 bacatina iii.
ES2096329T3 (es) Procedimiento para la preparacion de derivados del taxano.
ES2072627T3 (es) Derivados de piridina y n-oxido de piridina de diarilmetilpiperidinas o piperazinas, composiciones y uso de las mismas.
ES2146741T3 (es) Derivados de rapamicina utiles como inmunosupresores.
ES2188584T3 (es) Derivados heterociclicos de amina.
MY117896A (en) Quinazoline derivatives
ATE192649T1 (de) Stereochemische wortmanninderivate
ES2101044T3 (es) Taxanos alcoxi substituidos como agentes antitumorales.
ES2191005T3 (es) Taxanos sustituidos como agentes antitumorales.
DK81885D0 (da) Pyrido-benzothiazinderivater, fremgangsmaade til fremstilling deraf ogfarmaceutisk praeparat indeholdende mindst et saadant derivat
ES8507534A1 (es) Procedimiento para la preparacion de derivados benzopiranicos
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
ATE205837T1 (de) Chinoxaline, verfahren zu ihrer herstellung und ihre verwendung
ES2115600T3 (es) Derivados de 1-metilcarbapenem y procedimiento para su preparacion.
MX9306883A (es) Nuevos derivados de taxano, procedimiento para su obtencion y composicionfarmaceutica que los contiene.
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
ES2159922T3 (es) Nuevos derivados de bencimidazol, de benzoxazol y de benzotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
ES2133418T3 (es) Procedimiento para la preparacion de derivados del taxano.
ATE171374T1 (de) Verwendung von 1-(aminoalkyl)-3-quinoxalin-2-on derivaten zur herstellung von neuroprotektiven mitteln
BG50163A3 (bg) Метод за получаване на ацилови производни
ES2106936T3 (es) Derivados de carbazolona y procedimientos para su preparacion.
ES2062455T3 (es) Nuevos derivados de benzonaftiridina-1,8, su preparacion y las composiciones que les contienen.
PE23198A1 (es) Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos
HUP9901376A2 (hu) 1-Metil-karbapenem-származékok, alkalmazásuk, előállításuk, ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 663905

Country of ref document: ES